Antithrombotic therapy in cardiac embolism
- PMID: 21804782
- PMCID: PMC2994115
- DOI: 10.2174/157340310791658749
Antithrombotic therapy in cardiac embolism
Abstract
Anticoagulation is indicated in most cardioembolic ischemic strokes for secondary prevention. In many cardiac conditions, anticoagulation is also indication for primary stroke prevention, mainly when associated to vascular risk factors. Anticoagulation should be started as soon as possible, as it is safe even in moderate acute strokes. The efficacy of early anticoagulation after cardioembolic stroke in relation to outcome has not been assessed adequately, but there is evidence from animal models and clinical studies that anticoagulation with unfractionated heparin is associated with a better outcome mediated in part by its anti-inflammatory properties.
Keywords: Anticoagulation; heparin; inflammation.; oral anticoagulants; prevention.
Similar articles
-
Initiation of oral anticoagulation after acute ischaemic stroke or transient ischaemic attack: timing and complications of overlapping heparin or conventional treatment.Cerebrovasc Dis. 2008;26(2):171-7. doi: 10.1159/000145324. Epub 2008 Jul 15. Cerebrovasc Dis. 2008. PMID: 18628615 Clinical Trial.
-
Cardioembolic vs. noncardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies.Cerebrovasc Dis. 2000 Jan-Feb;10(1):39-43. doi: 10.1159/000016023. Cerebrovasc Dis. 2000. PMID: 10629345 Clinical Trial.
-
Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials.Stroke. 2007 Feb;38(2):423-30. doi: 10.1161/01.STR.0000254600.92975.1f. Epub 2007 Jan 4. Stroke. 2007. PMID: 17204681
-
Clinical benefit of early anticoagulation in cardioembolic stroke.Cerebrovasc Dis. 2008;25(4):289-96. doi: 10.1159/000118372. Epub 2008 Feb 27. Cerebrovasc Dis. 2008. PMID: 18303246 Review.
-
Cardioembolic stroke: an update.Lancet Neurol. 2003 Mar;2(3):177-88. doi: 10.1016/s1474-4422(03)00324-7. Lancet Neurol. 2003. PMID: 12849239 Review.
Cited by
-
Outcomes of Left Ventricular Assist Devices as Destination Therapy: A Systematic Review with Meta-Analysis.Life (Basel). 2025 Jan 3;15(1):53. doi: 10.3390/life15010053. Life (Basel). 2025. PMID: 39859993 Free PMC article. Review.
-
Antithrombotic medication for cardioembolic stroke prevention.Stroke Res Treat. 2011;2011:607852. doi: 10.4061/2011/607852. Epub 2011 Jun 22. Stroke Res Treat. 2011. PMID: 21822469 Free PMC article.
References
-
- Guidelines for management of ischaemic stroke and transient ischaemic attack. Cerebrovasc Dis. 2008;25(5):457–507. - PubMed
-
- Cervera A, Amaro S, Obach V, Chamorro A. Prevention of ischemic stroke: antithrombotic therapy in cardiac embolism. Curr Drug Targets. 2007;8(7):824–31. - PubMed
-
- Whitlon DS, Sadowski JA, Suttie JW. Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry. 1978;17(8):1371–7. - PubMed
-
- Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2008;133(6 Suppl):630S–69S. - PubMed
-
- Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2008;133(6 Suppl):257S–98S. - PubMed
LinkOut - more resources
Full Text Sources